GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » Ending Cash Position

SAGE (Sage Therapeutics) Ending Cash Position : $82.47 Mil (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Ending Cash Position?

Sage Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 was $82.47 Mil.

Sage Therapeutics's quarterly Ending Cash Position declined from Jun. 2024 ($102.73 Mil) to Sep. 2024 ($102.46 Mil) and declined from Sep. 2024 ($102.46 Mil) to Dec. 2024 ($82.47 Mil).

Sage Therapeutics's annual Ending Cash Position declined from Dec. 2022 ($163.97 Mil) to Dec. 2023 ($72.32 Mil) but then increased from Dec. 2023 ($72.32 Mil) to Dec. 2024 ($82.47 Mil).

Sage Therapeutics Ending Cash Position Historical Data

The historical data trend for Sage Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Ending Cash Position Chart

Sage Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,662.80 295.50 163.97 72.32 82.47

Sage Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.32 175.49 102.73 102.46 82.47

Sage Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sage Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=72.324+10.147
=82.47

Sage Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=102.459+-19.988
=82.47

Sage Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » Ending Cash Position
Comparable Companies
KROS ALLO HUMA OABI ALT SLDB TBPH STOK SVRA CMRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
SG7:Germany
Address
55 Cambridge Parkway, Cambridge, MA, USA, 02142
Website
https://www.sagerx.com
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Executives
Elizabeth Barrett director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer director C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas director, officer: See Remarks ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault officer: Chief Medical Officer C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi officer: Chief Commercial Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates director 88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud officer: Chief Scientific Officer 215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan officer: Chief Business Officer C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook officer: General Counsel 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul director C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi officer: See Remarks 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035